TITLE:
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

CONDITION:
Multiple Sclerosis

INTERVENTION:
AVP-923

SUMMARY:

      Pseudobulbar Affect is a condition characterized by frequent episodes of laughing and crying
      out of proportion. Other terms used to describe this condition include emotional lability,
      emotionalism, emotion incontinence, emotional discontrol, excessive emotionalism and
      pathological laughing and crying. AVP-923 is a new experimental drug that may assist in the
      reduction of uncontrolled episodes. This study will test the safety and efficacy of AVP-923
      in the treatment of MS patients suffering from pseudobulbar affect.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 68 Years
Criteria:

        Inclusion Criteria:

          -  18 to 68 years of age

          -  Confirmed diagnosis of Multiple Sclerosis

          -  Clinical history of pseudobulbar affect

        Exclusion Criteria:

          -  Sensitivity to quinidine or opiate drugs

          -  Recent diagnosed within 2 months with Multiple Sclerosis

          -  Patient on anti-depressants

          -  Patient with liver or kidney disease

          -  Patient with hypotension
      
